33081-06-0

Basic information

• Product Name: Nsc24635
• Synonyms: Nsc24635;2-amino-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-ol(SALTDATA: FREE);2-AMino-3,5,6,7-tetrahydro-cyclopentapyriMidin-4-one;2-Amino-6,7-dihydro-1H-cyclopenta[d]pyrimidin-4(5H)-one;2-amino-1,5,6,7-tetrahydrocyclopenta[d]pyrimidin-4-one
• CAS NO: 33081-06-0
• Molecular Formula: C₇H₉N₃O
• Molecular Weight: 151.17
• Mol File: 33081-06-0.mol
• Article Data: 5

Chemical Properties

• Melting Point: 346 °C
• Boiling Point: 327°Cat760mmHg
• Flash Point: 151.5°C
• Appearance: /
• Density: 1.65g/cm³
• Vapor Pressure: 0.000208mmHg at 25°C
• Refractive Index: 1.784
• Storage Temp.: 2-8°C
• PKA: 10.19±0.20(Predicted)
• CAS DataBase Reference: Nsc24635(CAS DataBase Reference)
• NIST Chemistry Reference: Nsc24635(33081-06-0)
• EPA Substance Registry System: Nsc24635(33081-06-0)

Safety Data

• Hazardous Substances Data: 33081-06-0(Hazardous Substances Data)

Usage

General Description

Nsc24635, also known as 5-Fluoroindole, is a chemical compound with the molecular formula C8H6FNO. It is a fluorinated derivative of indole, a heterocyclic aromatic organic compound. Nsc24635 has been studied for its potential use as a therapeutic agent in the treatment of cancer. Research has shown that it has antitumor activity, and it may have potential as a chemotherapeutic agent. In addition, Nsc24635 has been investigated for its potential use in the development of new drugs and pharmaceuticals. Its unique chemical properties and potential therapeutic effects make it an interesting candidate for further study in the field of medicinal chemistry and cancer research.

InChI:InChI=1/C7H9N3O/c8-7-9-5-3-1-2-4(5)6(11)10-7/h1-3H2,(H3,8,9,10,11)

Upstream product

• 50-01-1 guanidine hydrochloride 
• 10472-24-9 methyl 2-oxocyclopentane-1-carboxylate 
• 124-46-9 guanidine hydrogen carbonate 
• 611-10-9 2-ethoxycarbonyl-1-cyclopentanone 
• 113-00-8 guanidine nitrate 
• 593-85-1 guanidine carbonate 
• 593-85-1 diguanidine carbonate 

Downstream Products

• 1452669-66-7 4-N-(4-methoxyphenyl)-4-N-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine 
• 1452669-67-8 4-N-(3-methoxyphenyl)-4-N-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine 
• 1452669-68-9 4-N-(2-methoxyphenyl)-4-N-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine 
• 1452669-69-0 4-N-(4-ethoxyphenyl)-4-N-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine 
• 108758-99-2 4-(4-chloro-phenylsulfanyl)-6,7-dihydro-5H-cyclopentapyrimidin-2-ylamine 
• 108758-92-5 4-(4-chloro-phenoxy)-6,7-dihydro-5H-cyclopentapyrimidin-2-ylamine 
• 109261-50-9 4-benzyloxy-6,7-dihydro-5H-cyclopentapyrimidin-2-ylamine 
• 7511-83-3 2-Amino-6,7-dihydro-4-methylthio-5H-cyclopentapyrimidin 
• 61539-20-6 4-methoxy-6,7-dihydro-5H-cyclopentapyrimidin-2-ylamine 
• 5466-44-4 2-amino-3,5,6,7-tetrahydro-cyclopentapyrimidine-4-thione 
• 1899-39-4 2,4-Diamino-5,6-trimethylen-pyrimidin 
• 108990-72-3 6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amine 
• 5461-89-2 4-chloro-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amine 
• 5466-00-2 1,5,6,7-tetrahydro-cyclopentapyrimidine-2,4-dione 

Relevant articles and documents

COMPOUNDS AND METHODS FOR INHIBITION OF MULTIPLE MYELOMA

Novel compounds (small molecules) that potently and selectively inhibit MMP-13 (i.e., MMP-13 inhibitors) are used for treatment of multiple myeloma. The MMP-13 inhibitors described herein are highly selective for MMP-13 and when administered to an individ

Discovery and SAR of 6-alkyl-2,4-diaminopyrimidines as histamine H 4 receptor antagonists

This report discloses the discovery and SAR of a series of 6-alkyl-2-aminopyrimidine derived histamine H4 antagonists that led to the development of JNJ 39758979, which has been studied in phase II clinical trials in asthma and atopic dermatitis. Building on our SAR studies of saturated derivatives from the indole carboxamide series, typified by JNJ 7777120, and incorporating knowledge from the tricyclic pyrimidines led us to the 6-alkyl-2,4-diaminopyrimidine series. A focused medicinal chemistry effort delivered several 6-alkyl-2,4-diaminopyrimidines that behaved as antagonists at both the human and rodent H4 receptor. Further optimization led to a panel of antagonists that were profiled in animal models of inflammatory disease. On the basis of the preclinical profile and efficacy in several animal models, JNJ 39758979 was selected as a clinical candidate; however, further development was halted during phase II because of the observation of drug-induced agranulocytosis (DIAG) in two subjects.

Synthesis and hypoglycemic activity of 7,8-dihydro-6H-thiopyrano[3,2-d]pyrimidine derivatives and related compounds

-